These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 25638498

  • 1. Design, synthesis, and biological evaluation of novel 2-methylpiperazine derivatives as potent CCR5 antagonists.
    Hu S, Wang Z, Hou T, Ma X, Li J, Liu T, Xie X, Hu Y.
    Bioorg Med Chem; 2015 Mar 01; 23(5):1157-68. PubMed ID: 25638498
    [Abstract] [Full Text] [Related]

  • 2. Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists.
    Habashita H, Kokubo M, Hamano S, Hamanaka N, Toda M, Shibayama S, Tada H, Sagawa K, Fukushima D, Maeda K, Mitsuya H.
    J Med Chem; 2006 Jul 13; 49(14):4140-52. PubMed ID: 16821774
    [Abstract] [Full Text] [Related]

  • 3. Design, synthesis, and biological evaluation of novel piperidine-4-carboxamide derivatives as potent CCR5 inhibitors.
    Hu S, Gu Q, Wang Z, Weng Z, Cai Y, Dong X, Hu Y, Liu T, Xie X.
    Eur J Med Chem; 2014 Jan 13; 71():259-66. PubMed ID: 24316669
    [Abstract] [Full Text] [Related]

  • 4. Design, synthesis and biological evaluation of novel piperazine derivatives as CCR5 antagonists.
    Liu T, Weng Z, Dong X, Chen L, Ma L, Cen S, Zhou N, Hu Y.
    PLoS One; 2013 Jan 13; 8(1):e53636. PubMed ID: 23308267
    [Abstract] [Full Text] [Related]

  • 5. CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological evaluation of piperidine-4-carboxamide derivatives.
    Imamura S, Nishikawa Y, Ichikawa T, Hattori T, Matsushita Y, Hashiguchi S, Kanzaki N, Iizawa Y, Baba M, Sugihara Y.
    Bioorg Med Chem; 2005 Jan 17; 13(2):397-416. PubMed ID: 15598561
    [Abstract] [Full Text] [Related]

  • 6. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.
    Kondru R, Zhang J, Ji C, Mirzadegan T, Rotstein D, Sankuratri S, Dioszegi M.
    Mol Pharmacol; 2008 Mar 17; 73(3):789-800. PubMed ID: 18096812
    [Abstract] [Full Text] [Related]

  • 7. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
    Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, Takaoka Y, Shibayama S, Sagawa K, Fukushima D, Moravek J, Koyanagi Y, Mitsuya H.
    J Virol; 2004 Aug 17; 78(16):8654-62. PubMed ID: 15280474
    [Abstract] [Full Text] [Related]

  • 8. Orally active CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological activities of 1-benzazepine derivatives containing a sulfoxide moiety.
    Seto M, Miyamoto N, Aikawa K, Aramaki Y, Kanzaki N, Iizawa Y, Baba M, Shiraishi M.
    Bioorg Med Chem; 2005 Jan 17; 13(2):363-86. PubMed ID: 15598559
    [Abstract] [Full Text] [Related]

  • 9. Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety.
    Shiraishi M, Aramaki Y, Seto M, Imoto H, Nishikawa Y, Kanzaki N, Okamoto M, Sawada H, Nishimura O, Baba M, Fujino M.
    J Med Chem; 2000 May 18; 43(10):2049-63. PubMed ID: 10821717
    [Abstract] [Full Text] [Related]

  • 10. [2-(4-Phenyl-4-piperidinyl)ethyl]amine based CCR5 antagonists: derivatizations at the N-terminal of the piperidine ring.
    Duan M, Aquino C, Ferris R, Kazmierski WM, Kenakin T, Koble C, Wheelan P, Watson C, Youngman M.
    Bioorg Med Chem Lett; 2009 Mar 15; 19(6):1610-3. PubMed ID: 19233649
    [Abstract] [Full Text] [Related]

  • 11. Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection.
    Shin N, Solomon K, Zhou N, Wang KH, Garlapati V, Thomas B, Li Y, Covington M, Baribaud F, Erickson-Viitanen S, Czerniak P, Contel N, Liu P, Burn T, Hollis G, Yeleswaram S, Vaddi K, Xue CB, Metcalf B, Friedman S, Scherle P, Newton R.
    J Pharmacol Exp Ther; 2011 Jul 15; 338(1):228-39. PubMed ID: 21459966
    [Abstract] [Full Text] [Related]

  • 12. Discovery of orally available spirodiketopiperazine-based CCR5 antagonists.
    Nishizawa R, Nishiyama T, Hisaichi K, Hirai K, Habashita H, Takaoka Y, Tada H, Sagawa K, Shibayama S, Maeda K, Mitsuya H, Nakai H, Fukushima D, Toda M.
    Bioorg Med Chem; 2010 Jul 15; 18(14):5208-23. PubMed ID: 20542438
    [Abstract] [Full Text] [Related]

  • 13. Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.
    Skerlj R, Bridger G, Zhou Y, Bourque E, McEachern E, Metz M, Harwig C, Li TS, Yang W, Bogucki D, Zhu Y, Langille J, Veale D, Ba T, Bey M, Baird I, Kaller A, Krumpak M, Leitch D, Satori M, Vocadlo K, Guay D, Nan S, Yee H, Crawford J, Chen G, Wilson T, Carpenter B, Gauthier D, Macfarland R, Mosi R, Bodart V, Wong R, Fricker S, Schols D.
    J Med Chem; 2013 Oct 24; 56(20):8049-65. PubMed ID: 24090135
    [Abstract] [Full Text] [Related]

  • 14. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-methyl piperazine as a key pharmacophore element.
    Tagat JR, McCombie SW, Steensma RW, Lin S, Nazareno DV, Baroudy B, Vantuno N, Xu S, Liu J.
    Bioorg Med Chem Lett; 2001 Aug 20; 11(16):2143-6. PubMed ID: 11514156
    [Abstract] [Full Text] [Related]

  • 15. Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists.
    Latinovic O, Heredia A, Gallo RC, Reitz M, Le N, Redfield RR.
    Antiviral Res; 2009 Jul 20; 83(1):86-9. PubMed ID: 19501260
    [Abstract] [Full Text] [Related]

  • 16. Discovery of novel (S)-alpha-phenyl-gamma-amino butanamide containing CCR5 antagonists via functionality inversion approach.
    Zhang HS, Feng DZ, Chen L, Long YQ.
    Bioorg Med Chem Lett; 2010 Apr 01; 20(7):2219-23. PubMed ID: 20207141
    [Abstract] [Full Text] [Related]

  • 17. Design, synthesis, and biological activity of novel 1,4-disubstituted piperidine/piperazine derivatives as CCR5 antagonist-based HIV-1 entry inhibitors.
    Dong MX, Lu L, Li H, Wang X, Lu H, Jiang S, Dai QY.
    Bioorg Med Chem Lett; 2012 May 01; 22(9):3284-6. PubMed ID: 22464131
    [Abstract] [Full Text] [Related]

  • 18. [CCR5, a new target of anti-HIV drugs].
    Han YX, Jiang JD.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Oct 01; 25(5):635-9. PubMed ID: 14650176
    [Abstract] [Full Text] [Related]

  • 19. Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.
    Seto M, Aikawa K, Miyamoto N, Aramaki Y, Kanzaki N, Takashima K, Kuze Y, Iizawa Y, Baba M, Shiraishi M.
    J Med Chem; 2006 Mar 23; 49(6):2037-48. PubMed ID: 16539392
    [Abstract] [Full Text] [Related]

  • 20. Identification of peptide ligands to the chemokine receptor CCR5 and their maturation by gene shuffling.
    Vyroubalova EC, Hartley O, Mermod N, Fisch I.
    Mol Immunol; 2006 Apr 23; 43(10):1573-8. PubMed ID: 16280164
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.